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Abstract
Background: Bovine colostrum is proposed as a nutritional countermeasure to the risk of upper respiratory
symptoms (URS) during exercise training. The aim of this systematic review and meta-analysis was to estimate the
size of the effect of bovine colostrum supplementation on URS.
Methods: Databases (CDSR, CENTRAL, Cinahl, ClinicalTrials.gov, Current Controlled Trials, DARE, EMBASE, Medline,
PROSPERO and Web of Science) of published, unpublished and ongoing studies were searched for randomised
controlled trials of healthy adults (≥18 years), evaluating the effect of oral bovine colostrum supplementation
compared to a concurrent control group on URS.
Results: Five trials (152 participants) met the inclusion criteria, all of which involved individuals involved in regular
exercise training. Over an 8–12 week follow-up period, bovine colostrum supplementation when compared to
placebo significantly reduced the incidence rate of URS days (rate ratio 0.56, 95 % confidence intervals 0.43 to 0.72,
P value < 0.001) and URS episodes (0.62, 0.40 to 0.99, P value = 0.04) by 44 and 38 % respectively. There were limited
data and considerable variation in results of included studies for duration of URS episodes hence a meta-analysis of
this outcome was deemed inappropriate. The risk of bias assessment in this review was hindered by poor reporting
practices of included studies. Due to incomplete reporting of study methods, four of the five studies were judged
to have a moderate or high risk of overall bias. Our findings must be interpreted in relation to quantity and quality
of the available evidence.
Conclusions: The present systematic review and meta-analysis provides evidence that bovine colostrum
supplementation may be effective in preventing the incidence of URS days and episodes in adults engaged in
exercise training. The fact that the majority of included studies did not report significant effects on URS outcomes
mitigates concerns about publication bias. The point estimates of the random-effects meta-analyses are greater
than the smallest clinically important difference, but the low precision of the individual study estimates means the
evidence presented in this review needs to be followed up with an appropriately designed and adequately
powered, randomised control trial.
Trial registration: Protocol was registered (CRD42015014925) on the International Prospective Register of
Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO/).
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Background
Upper respiratory tract infections represent a leading
cause for consultations in primary health care [1]. Life-
style and behavioural factors are key determinants of in-
fection risk [2]. Evidence from cross-sectional and
longitudinal studies suggests that athletes are susceptible
to symptoms of upper respiratory tract infections during
periods of strenuous exercise training and immediately
after competition [3–7]. Given the lack of feasibility in
identifying pathogenic causes of infections in most re-
search settings [1], the majority of findings are limited to
self-reporting by athletes whereby upper respiratory
symptoms (URS) has become the accepted reporting
standard in exercising populations [8]. Regardless of
whether URS are due to infectious causes or other in-
flammatory stimuli (allergies, airway irritation) mimick-
ing infection, the potential for a negative impact (e.g.
impaired performance) on the individual athlete may be
the same [8, 9]. Despite being an active and rapidly
growing area of research, there remains a lack of effect-
ive countermeasures to risk of URS during exercise
training [10]. There is a clear need for evidence-based
interventions that can reduce the burden of URS in at
risk populations such as endurance athletes.
Bovine colostrum (BC) is the initial milk produced by
a cow in the first few days following parturition. In con-
trast to mature milk, BC is rich in bioactive components
including growth factors (e.g. epidermal growth factor),
immunological mediators (e.g. immunoglobulins) and
antimicrobial peptides (e.g. lactoferrin) that are homolo-
gous to human colostrum. The greater concentrations of
these bioactive constituents in BC have led to proposed
benefits towards human immune health [11]. Unlike the
passive transfer of immunity that is important for the
development of neonatal calves, it is proposed that the
small bioactive constituents of BC, which survive diges-
tion, or their metabolites that appear after consumption,
have direct effects on human immunity [12]. A recent
systematic review exploring the potential applications of
BC (including risk of URS) concluded that BC supple-
mentation may enhance or protect host defence under
certain detrimental situations (e.g. exercise-induced im-
mune dysfunction) but the exact clinical benefits are yet
to be established [13]. However, findings from this re-
view should be interpreted with caution as data of in-
cluded studies were not statistically combined to
quantify effect size, we are also aware of at least one
other study [14] on the risk of URS that was not
included.
The current evidence of the scientific validity of BC is
limited, and the level of evidence used in support of its
claims falls below that acceptable in the medical com-
munity. While the evidence indicates that BC may have
a role in reducing the risk of URS, there is currently no
systematic review and meta-analysis that has synthesised
the effect of BC interventions on URS. The aim of this
study was to systematically review randomised con-
trolled trials in order to estimate the size of the effect of
BC supplementation on URS. Specifically, we examined
whether BC supplementation reduces the incidence rate
of URS days or episodes and duration of URS episodes
during exercise training.
Methods
Methods of analysis and inclusion criteria were specified
in advance and documented in a protocol that was regis-
tered (CRD42015014925) on the International Prospective
Register of Systematic Reviews (http://www.crd.york.a-
c.uk/PROSPERO/).
Eligibility criteria
This review considered studies for inclusion if they were
randomised controlled trials, evaluating the effect of oral
supplementation of non-hyperimmune BC on URS out-
comes among healthy adults (≥18 years).
Study identification
To identify any existing relevant systematic reviews,
published and ongoing trials the following electronic da-
tabases were searched from inception to July 2015:
Cinahl, ClinicalTrials.gov, Cochrane Central Register of
Controlled Trials; CENTRAL, Cochrane Database of
Systematic Reviews; CDSR, Current Controlled Trials,
DARE, EMBASE, Medline, PROSPERO and Web of Sci-
ence. We also searched the British library (ETHOS) and
other library services within our Institution for obtaining
non-published data. No restrictions on language were
imposed. Key terms used to search trials registers and
databases were terms for BC interventions (e.g. bovine
colostrum, see Additional file 1). Database searching was
supplemented with internet searching (e.g. Google
Scholar), forward and backward citation tracking from
systematic reviews and included studies, and contact
with study authors, experts and research groups. Search
results were downloaded to Endnote. Duplicate citations
were removed and titles and abstracts screened inde-
pendently by two reviewers against the inclusion criteria.
Where studies could not be excluded based on title or
abstract, two reviewers assessed full text papers for rele-
vance independently. Any discrepancies were resolved
through discussion, or where required a third reviewer.
Data abstraction
We developed, tested and refined a structured data ex-
traction template. For each study, one reviewer extracted
data, which was cross-checked for accuracy by a second
reviewer. Information was extracted from each included
trial on: characteristics of participants (age, gender,
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inclusion criteria, exclusion criteria); type of intervention
(non-hyperimmune BC vs placebo, dose, duration, fre-
quency/timing, diluter); type of outcome measure (self-
reported total number of days with URS, number of
URS episodes, duration of episodes).
The Cochrane risk of bias assessment tool was used to
assess studies for accuracy of key quality issues such as
method of randomisation, blinding and follow up [15].
Each domain was classified as adequate, unclear or inad-
equate and the overall risk of bias for each study was
interpreted as follows: low risk of bias, (all criteria
graded adequate); moderate risk of bias (one criterion
graded inadequate or two graded unclear) and high risk
of bias (more than one criterion inadequate, more than
two graded unclear). As only five studies were included,
all four reviewers examined and agreed on the risk of
bias for each domain for each included study.
Data analysis
All analyses were conducted using Review Manager ver-
sion 5.3. The primary outcome measure was the rate ra-
tio of URS days. The secondary summary measures were
the rate ratio of episodes of URS and the mean duration
of an episode of URS. We contacted study authors to
obtain missing numerical outcome data and in cases
where studies only reported URS as one of the above
outcomes, we verified that no additional data were avail-
able. Rate ratio of URS days and episodes of URS were
calculated using the incidence rate in BC groups divided
by incidence rate in placebo groups. The incidence rate
for each group was based on the total number of URS
days or (study defined) URS episodes divided by the total
number of days of observation. The (natural) logarithms
of the rate ratios and the standard error of the rate ratio
were combined statistically using the generic inverse-
variance random-effects model according to [15]. Dur-
ation of URS episodes was analysed as a continuous out-
come and expressed as the between-groups difference in
mean duration of episodes. Random-effect models were
used in all meta-analyses, as they are more conservative
than the fixed effects models since, by incorporating
within- and between-study variance, the confidence in-
tervals for the summary effect are wider. This is based
on the underlying assumption that the individual study
estimates are not identical but follow a normal distribu-
tion. Statistical heterogeneity in any random-effect
meta-analyses was assessed by the I2 test [15]. The I2
statistic indicated the proportion of variation among ef-
fect estimates above that expected by chance. In cases
where heterogeneity was considered to be important
(I2 > 40 %) [15], sources of clinical and methodological
diversity were explored. We attempted to explore the ef-
fect of BC on the primary outcome (rate ratio of days of
URS) in pre-specified subgroups of study stratified by
dose (high versus low) or duration of intervention. The
robustness of results was assessed in separate sensitivity
analyses that excluded trials with high risk of bias.
Results
After removal of duplicates, the search strategy identi-
fied 3936 distinct citations, of which 3914 were excluded
during the initial screening phase (Fig. 1). For the
remaining 22 citations, full-text papers were ordered,
obtained and independently assessed against the eligibil-
ity criteria, with two discrepancies resolved by discus-
sion. Studies were included if the allocation to BC and
control groups were randomised or based on a quasi-
random method. Five studies (23 %) met the inclusion
criteria [14, 16–19]. The main reasons for exclusion of
full-text papers were studies not reporting URS out-
comes (n = 11), non-randomised study designs (n = 4)
and BC combined with other interventions (n = 3).
Characteristics of included studies
The five included studies were published between 2006
and 2014 (Table 1). Of the five studies, two were con-
ducted in Australia [18, 19], two in New Zealand [16,
17] and one in Wales [14]. One of these trials was expli-
citly identified in the study report as being a pilot study
[19]. The five trials randomised 152 participants (80 %
males), with sample size ranging from 10 to 53.
Participants within all included trials were regularly in-
volved in endurance exercise, defined by training volume
and/or participation in a training program for a com-
petitive event. Participants were highly trained cyclists
[18, 19], recreational distance runners [16], elite swim-
mers [17] or those recreational active [14] from a range
of endurance-based training (running, cycling, swim-
ming, triathlon, team games). In-training eligibility was
determined by self-report of exercise training in three
[14, 16, 17] of the studies, and membership of a team
that was ‘in-training’ in two [18, 19] of the studies.
Participants during all trials self-reported physical ac-
tivity. Four of the five studies used daily training diaries/
logs [16–19], and one study [14] required participants to
complete the international physical activity question-
naire on a weekly basis. Aside from the supplementation,
participants in all of the trials continued with their usual
diets during trial periods.
Common participant exclusion criteria in the individ-
ual trials were the use of supplements [14, 16–18], in-
tolerance to lactose [16, 17] or use of medication [14,
16, 17]. One study [14] also stipulated that participants
should be non-smokers and free from infectious illness
for 4 weeks prior to the study.
All trials compared BC to placebo. Supplementation
period in these trials was 8 weeks [18, 19], 10 weeks
[16], or 12 weeks [14, 17]. All studies included provision
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of BC in powdered form where daily dosage of the BC
intervention was either 10 g [16, 18, 19] or 20 g [14, 17].
In two of the trials [18, 19], the placebo comprised of
whey protein, two trials [16, 20] used skimmed milk,
which was consumed at the identical dose, frequency,
and duration as the BC supplement. One trial [14] re-
ported use of a placebo in line with a previously pub-
lished study [20]; an isoenergetic/isomacronutrient
mixture of milk protein concentrate and skimmed milk
powder. BC and placebo powdered supplements were
isocaloric in three studies [14, 17, 19] and matched for
digestible protein content in one trial [16]. Although
each study reported to be a double-blind trial, none
assessed the extent to which participants may have de-
duced their group allocation / treatment regimen.
Outcomes relevant to incidence or duration of URS
were not specified as primary outcomes in any of the
five trials, although three [14, 16, 17] did include them
within their “main outcomes”. Pre-specified checklists,
self-reported by participants, were used to record URS
in all of the trials but a physician did not verify these
medically. Studies used measurement instruments that
were either previously published [14, 16, 17] or validated
(Wisconsin Upper Respiratory Symptom Survey [18, 19].
URS days were included in the analysis within each of
the included studies when two or more consecutive days
were reported. Although none of the included studies
undertook pathogenic aetiology of symptoms, three
studies had additional criteria for URS to be classified as
an episode. Two studies [18, 19] required the presence
of two or more URS to be recorded (e.g., runny or stuffy
nose, sore or scratchy throat, sneezing, headache, fever,
cough) while the other [14] classified an episode on a
pre-defined symptom score which ultimately required at
least three symptoms (sore throat, catarrh in the throat,
runny nose, cough, repetitive sneezing, fever, persistent
muscle soreness, joint aches and pains, weakness or
headache) of a moderate severity to last for a minimum
of 2 days, or two moderate symptoms to last for 3 days.
Included studies required participants to be free of
symptoms for a period of 3 days [16] or 7 days [14, 18,
19] before an URS episode was considered separate to a
previous episode. Number of URS days or episodes and
duration of episodes were treated as continuous out-
comes in all of the studies and interpreted as a differ-
ence in means. Comparisons in the proportions of BC
and placebo groups to report incidence of URS was also
presented by two studies [14, 17].
The included studies varied for risk of bias (Table 2).
Three of the five studies were considered to have a
high overall risk of bias [14, 16, 17], one was moder-
ate [19] and one low risk of bias [18]. The risk of
bias assessment was hindered by poor reporting. No
individual domain across all studies was graded inad-
equate for risk of bias. It was an accumulation of sev-
eral domains classified as unclear (due to insufficient
reporting) that resulted in an overall moderate or
high risk of bias for included studies.
Records identified 
through search strategy 
(n = 5803) 
Duplicate citations removed  
(n = 1867)
Records screened 
(n = 3936)
Records excluded based on: 
title (n = 3869)
abstract (n = 45)
Full-text articles assessed 
for eligibility 
(n = 22)
Excluded studies (n = 17)a
No symptom data reported n = 11
Not randomised design n = 4
Combination intervention n = 3
Participants symptomatic upon entry n = 2
Fractionated bovine colostrum n = 1
Included studies 
(n = 5)
Studies in meta-analysis 
(n = 5)
Fig. 1 Flow diagram of study selection. aSome studies excluded for multiple reason.
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Table 1 Characteristics of included studies
Study (country) Sample size Age, years Proportion of males Inclusion criteria Exclusion criteria Intervention, dose,
frequency/timing,
duration, diluter
Placebo
Crooks et al. 2006 [16]
(New Zealand)
BC: 18
PLA: 17
Median (range)
BC: males, 46 (35–57),
females, 43 (30–53)
0.48 Pack runs≥ 1 week,
marathon training
over last 5 years,
age < 60 year
Lactose intolerant,
allergy to cows milk,
whey-protein
supplements,
treatment for any
diagnosed condition
Oral BC (Immulac,
NZMP Ltd, Auckland,
New Zealand), 26 g of
powdered sachets/day
corresponding to 10 g
of BC, daily, 12 weeks,
chocolate powder with
125 ml water
Skim milk matched for
equivalent digestible
protein content. Flavours
and colours added to
match BCPLA: males, 48 (36–56)
females, 51 (41–58)
Crooks et al. 2010 [17]
(New Zealand)
BC: 12
PLA: 13
Mean ± standard error
BC: males, 17 ± 1
females, 20 ± 1
0.57 Participating in training
program prior to The
Auckland Swimming
Championships
Lactose intolerant,
allergy to cows milk,
whey-protein,
immunological-modulating
supplements, treatment for
any diagnosed condition
Oral BC (Immulac,
NZMP Ltd, Auckland,
New Zealand), 52 g
of powdered sachets/day
corresponding to 20 g of
BC, 10 g morning & evening,
10 weeks, 125 ml water
Skim milk powder, matched
for equivalent protein, fat
and carbohydrate content
PLA: males, 19 ± 1,
females, 18 ± 1
Jones et al. 2014 [14]
(Wales)
BC: 25
PLA: 28
Mean ± standard deviation
BC: 31 ± 14
PLA: 32 ± 13
1.00 ≥3 h moderate-
vigorous endurance
exercise/week
Smoker, medication or
other supplements,
infectious illness in
4 weeks prior to study
Oral BC (Neovite, UK,
London), 20 g/day,
10 g with morning
& evening meal, 12 weeks
Isoenergetic/isomacronutrient
PLA as described elsewhere
Shing et al. 2007 [18]
(Australia)
BC: 14
PLA: 15
Mean ± standard error
BC: 29 ± 1
PLA: 27 ± 2
1.00 Cyclists racing
competitively ≥ 2
months, consistent
training volumes≥ 2
months
Dietary supplements 1
month prior to study
Oral BC (Numico Research
Australia, South Australia,
Australia), 10 g/day,
morning, 8 week 1 day,
50 ml water + 100 ml milk
Whey protein (Alacen 80;
Fonterra Co-op group
Limited, Auckland,
New Zealand)
Shing et al. 2013 [19]
(Australia)
BC: 4
PLA: 6
Mean ± standard error
BC: 22 ± 3
PLA: 23 ± 2
1.00 Cyclists racing
competitively
≥3 months.
Consistent training
volumes≥ 2 months
None reported Oral BC (Numico Research
Australia, South Australia,
Australia), 10 g/day, morning,
8 weeks and 5 days, 50 ml
water + 100 ml milk
Whey protein concentrate
(Alacen 80; Fonterra
Co-op group Limited,
Auckland, New Zealand)
BC bovine colostrum, PLA placebo
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Effect of bovine colostrum on upper respiratory
symptoms (URS)
Rate ratio of URS days
Five trials reported the number of URS days [14, 16–19].
There were 73 participants in the BC group and 79 in
the placebo group. The point estimate of effect for each
of the included trials indicated a lower incidence rate of
URS days with BC. Pooled analyses from the five trials
demonstrated a significant effect of BC supplementation
on the rate of URS days (rate ratio 0.56, 95 % confidence
intervals 0.43 to 0.72, P value < 0.001) (Fig. 2). Moderate
level of statistical heterogeneity was detected among trial
level effects when all five trials were included (Chi2 =
8.15; df = 4, P value = 0.09; I2 = 51 %). Compared to other
included studies, one study [18] was limited to swim-
mers only. Removal of Crooks [18] reduced the I2 to
zero but the effect of BC on URS days remained signifi-
cant (0.64, 0.53 to 0.78, P value < 0.001).
Rate ratio of episodes of URS
Four trials reported the number of URS episodes [14, 16,
18, 19]. There were 61 participants in the BC group and
66 in the placebo group. The point estimate of effect for
each of the included trials indicated a lower incidence
rate of URS days with BC. Pooled analyses showed that
across these trials, the episode rates of URS were signifi-
cantly lower with BC (rate ratio 0.62, 95 % confidence
intervals 0.40 to 0.99, P value = 0.04) (Fig. 3). Statistical
heterogeneity was not apparent in this outcome (Chi2 =
0.76; df = 3, P value = 0.86; I2 = 0 %).
Duration of URS episodes
Three trials reported the duration of URS episodes [14,
18, 19]. There were 43 participants in the BC group and
49 in the placebo group. One trial [19] had insufficient
data to be used in pooled analysis having observed a low
number of URS episodes (one event, duration of 5 days)
during BC supplementation (mean ± standard deviation
of placebo group: 4 ± 1.4 days). The other two included
trials reported shorter [14] (Mean difference −2.0, 95
confidence intervals −4.7 to 0.7) or longer [18] (2.1, 0.2
to 4.0) duration of URS episodes with BC supplementa-
tion. Given the limited data and considerable variation
in results, particularly the inconsistency in the direction
of effect, a meta-analysis of this outcome was deemed
inappropriate.
Subgroup and sensitivity analyses
There were too few studies for meaningful synthesis of
subgroups and sensitivity analyses of our primary out-
come (URS days). However, if further data become avail-
able, these should be included in a future meta-analysis.
In particular, the trend for larger effects in trials [14, 16]
using a daily BC dose of 20 g (rate ratio 0.48, 95 % confi-
dence intervals 0.32 to 0.71) compared to trials using
10 g [17–19] (0.66, 0.53 to 0.83, P value < 0.001) war-
rants further attention.
Discussion
Summary of main findings
The review identified five randomised controlled trials
[14, 16–19] evaluating the short-term effects of BC on
URS during exercise training. Synthesised data from five
[14, 16–19] trials showed a statistically significant effect
in which, compared to placebo, BC reduced the rate of
URS days by 44 %. Similarly, synthesised data from four
trials [14, 16, 18, 19] indicated statistically significant ef-
fects favouring BC with a 38 % reduction in episode
rates of URS.
Strengths and weaknesses of the study
The study adhered to the pre-specified protocol
using appropriate methods to select, evaluate and
synthesise all the relevant evidence. A comprehensive
search for published and unpublished studies, which
included multiple electronic databases, scanning of
bibliographies and contact with authors yielded five
published studies. To date there are only a limited
number of randomised controlled trials in this area
with small sample sizes. A strength of this review is
that it presents the first meta-analyses synthesising
the effects of BC supplementation on URS. The
point estimates for the effect of BC on the rate of
URS days and episodes demonstrate a small [21], but
clinically important reduction. The estimate of the
effect of BC on URS did indicate the presence of a
moderate statistical heterogeneity. Whilst we
Table 2 Risk of bias within trials
Study or
subgroup
Random sequence
generation
Allocation
concealment
Blinding: participants and
personnel
Incomplete outcome
data
Overall
risk
Crooks 2006 [16] unclear unclear unclear adequate high
Crooks 2010 [17] unclear unclear unclear adequate high
Jones 2014 [14] unclear unclear unclear adequate high
Shing 2007 [18] adequate adequate adequate adequate low
Shing 2013 [19] adequate adequate adequate unclear moderate
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identified a potential source of heterogeneity, the in-
clusion or exclusion of this individual study estimate
would not modify the conclusions drawn in this re-
view. The small sample sizes and hence the low
number of events (symptoms, episodes) led to wide
confidence intervals for the point estimates. For the
reduction in URS days, the lower confidence limit is
still greater than the smallest clinically important
difference (ratio 0.90; 10 % change in incidence)
[22]. As the entire range of the confidence interval
for the effect of BC on URS episodes does not ex-
ceed the threshold of clinical usefulness, we cannot
exclude the possibility that the reduction in episodes
is of a magnitude not considered clinically
worthwhile.
The lack of identification and hence inclusion of un-
published evidence is often considered a limitation in
systematic reviews. Effects estimated from published
studies may be inflated due to bias towards the non-
publication of studies with non-significant effects. We
did not have a sufficient number of individual study esti-
mates to use a funnel plot to detect such bias in this re-
view. However, the fact that the majority of included
studies did not report significant effects on URS out-
comes mitigates concerns about publication bias. The
decision to publish appears to be independent of an ob-
served effect. There was potential for bias in all of the
trials included in this meta-analysis, however no individ-
ual risk of bias domain was classified as high risk. There
were many items where the risk of bias was unclear,
primarily due to incomplete reporting by authors. Con-
sequently, there is a degree of uncertainty in relation to
bias for the included evidence.
The incidence of URS in the included studies in this
review was on a self-reported basis only. Although inci-
dence during exercise training and/or around periods of
competition has long been considered to be of an infec-
tious origin, both pathogen identification and physician
confirmation of URS are uncommon in research settings
[8]. Due to the large number of potential causative path-
ogens [1], and hence the cost associated with such diag-
nostic procedures, pathogen identification is not always
feasible [8]. Physician diagnosis, once considered the
‘gold standard’, has also come under scrutiny due to dis-
crepancies with laboratory evaluation of bodily fluids
from symptomatic individuals [3]. It has been argued,
that self-diagnosis (at least of infections) and not phys-
ician diagnosis is the most reasonable approach for re-
search studies given the familiarity of the general
population with such symptoms [23]. However, the lim-
ited range of physiological responses within the upper
respiratory tract means that there are similarities in the
early signs and symptoms (sore throat, sneezing, runny
nose, and nasal congestion) of airway irritation, infection
and allergy [23, 24]. The included studies had made fur-
ther attempts to at least aid the interpretation of the
underlying cause of URS (defining the minimum number
of days/symptoms before consideration). However, as
there was no pathological investigation, we cannot be
certain that all self-reported URS were of an infectious
Fig. 3 Trial-level data, effect estimates and forest plot of comparison for the rate ratio of episodes of upper respiratory symptoms
Fig. 2 Trial-level data, effect estimates and forest plot of comparison for the rate ratio of days with upper respiratory symptoms
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cause. Therefore, we have maintained the use of URS (as
opposed to upper respiratory tract infection, URTI) in
this review, in line with the recommendations placed
within a position statement led by experts of the Inter-
national Society of Exercise Immunology [8].
All of the included studies were randomised, placebo-
controlled trials. Two [16, 17] of the included trials re-
ported that they used skimmed milk for a placebo, two
[18, 19] used whey protein and one [14] used an isoener-
getic and isomacronutrient mixture of skimmed milk
and milk protein concentrate. Each of the included stud-
ies provided their respective BC and placebo groups with
similar amounts of protein. The only difference between
the placebo and test drug should be the absence of a pu-
tative active or characteristic feature [25]. Any negative,
positive, or same direction placebo effects could result
in the appearance of misleading negative, positive, or
non-significant effects of the experimental substance. An
effect of BC has been demonstrated despite use of pla-
cebo substances (whey peptides) within included studies
[18, 19] that also possess immune-modulating properties
[26] and hence potential to benefit URS outcomes.
Comparison with other studies
There is currently no meta-analysis that has assessed the
effect of BC on URS. We are not aware of another re-
view evaluating the effect of BC on URS in healthy
adults, although one review does discuss the clinical ap-
plications of BC therapy [13]. The aim of the previous
review [13] was to evaluate the evidence in relation to
the effect of BC on any quantifiable change in a health
or performance related clinical or paraclinical parameter.
Unlike the current review, Rathe et al. [13] did not in-
clude the use of a control group as a criterion for inclu-
sion of individual studies, nor did they statistically
combine the findings of these studies into a single nu-
merical estimate of effect. Also, the three-item jaded
scale was used to evaluate the methodological quality of
the included studies, which has often been criticised for
its over-simplification of the process, and a greater focus
on reporting quality rather than methodological quality.
The present study reduces uncertainty concerning the
clinical effect of BC.
Future research
The low precision of the individual study estimates (as a
result of small sample sizes and hence low number of
events) within the present meta-analyses widens the
confidence intervals for the point estimate of the effect
of BC. The evidence presented in this review needs to be
followed up with an appropriately designed and ad-
equately powered, randomised control trial. None of the
included studies reported an a priori sample size calcula-
tion to determine the effect of BC on URS. Majority of
the studies were limited by expressing URS incidence as
a continuous outcome measure and interpreting the ef-
fects of BC on mean differences. The incidence of URS
days and episodes are count data whereby authors
should express the outcomes as rates or ratios and ana-
lyse using a Poisson regression model with an overdis-
persion correction. Future studies should include an a
priori sample size calculation, powered and justified on
the smallest clinically important effect which has been
proposed to be a 10–20 % change in the incidence of ill-
ness (ratio of 0.9/0.83) [22].
It has long been considered that transient perturba-
tions in host immunity following strenuous training
and/or competition predispose athletes to an “open win-
dow” of increased susceptibility to infectious (patho-
genic) causes of URS [27]. More recently, non-infectious
(e.g. airway irritation, allergies, asthma) hypotheses have
been proposed to explain a proportion of the incidence
of self-reported URS following exercise [8]. Given the
uncertainty surrounding the underlying causes of URS
with exercise [8], there may be a number of potential
mechanisms responsible for the effects of BC on URS
during exercise training. An in-depth discussion of
underlying mechanisms of the effects of BC is beyond
the scope of this review. The current available evidence
does at least suggest that BC counters perturbations in
intestinal barrier integrity, immune cell functions and
salivary antimicrobial peptides (AMPs) following strenu-
ous exercise [12]. Future studies should consider bio-
logically sensitive, clinically relevant in vivo markers of
immunity to support interpretation [28], although im-
mune measures should always be viewed as secondary
parameters that complement primary (clinical symptom)
endpoints and not vice versa. Although it is the presence
of symptoms that are perceived as a nuisance at the indi-
vidual level, not the infection per se [1], it would be pru-
dent for future research, where possible, to conduct
more exhaustive clinical screening of participants upon
study entry and perform pathological testing to identify
infectious from non-infectious causes of URS. We did
not synthesise the effect of BC on duration of URS epi-
sodes, further trials are needed to measure this outcome
and the severity of episodes, which was not considered
in this review. These additions would not only help the
interpretation of changes in URS with BC during exer-
cise training, but also inform the medical and scientific
community of other target populations (immunocom-
promised, inflammatory, allergic) that may benefit from
BC supplementation.
There were a limited number of studies to undertake a
pre-planned analysis of trials stratified by dosage and
duration of BC intervention, but tentative evidence pro-
vided in this review suggests that there may be a dose-
response effect of BC. The reduction in the incidence
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rate of URS days with BC on average was larger (by
18 %) in studies using 20 g compared to 10 g. It is
worthy to note that this finding is purely observational
by nature whereby a head to head randomised compari-
son of different doses is required. Research to confirm
the minimum and optimum dose for the effect of BC on
incidence and duration of URS should be considered. It
has previously been suggested that some of the immune-
modulatory effects of BC are due to bioactive compo-
nents that become biologically active upon digestion of
BC [12]. Dose alone is not the only factor that could lead
to variation in the magnitude of exposure to such bio-
active (health-promoting) components. Composition of
these bioactive components is superior during the first
milkings and subsequently decreases during the first
3 days of lactation to those of mature milk [29]. In order
to further clarify the effects of BC between studies, in-
vestigations should specify collection and processing
methods of BC (e.g. timing of collection period) and
provide a composition profile of the product (i.e. provide
evidence of product quality such as components found
in early milkings).
Our findings must be interpreted in relation to quan-
tity and quality of available evidence. The risk of bias as-
sessment in this review was hindered by poor reporting
practices of included studies. Although the quantity and
quality of the evidence was less than ideal, we do not
consider these limitations to be sufficient to dismiss the
findings of this review. However, future trials are urged
to improve on the current reporting of parallel-group
randomised controlled trials on BC by adhering to Con-
solidated Standards of Reporting Trials (CONSORT)
guidelines that facilitate critical appraisal and
interpretation.
In general BC supplementation is considered to be safe
and well tolerated in humans [30]. One study included
in this review reported side effects presenting as stom-
ach problems, in females only, which were mild and gen-
erally disappeared with time [16]. Another study
indicated no side effects with BC supplementation [17].
None of the other included studies reported side effects
or adverse reactions following BC supplementation.
However, it is unclear if this was due to lack of incidence
or a lack of measurement within the studies. Future re-
search is recommended to monitor and report findings
on side effects to help establish the safety profile of BC
and its applicability as an intervention in other (e.g. clin-
ical) populations.
Conclusion
This systematic review and meta-analysis shows that oral
supplementation of BC reduces the incidence rates of
URS days and episodes in adults involved in exercise
training. This may have important implications for the
field of sports medicine, which to date has limited evi-
dence for supporting the use of nutritional countermea-
sures against URS under conditions of physiological
stress. In the absence of side effects, future prospective
studies are recommended in other at risk groups (e.g.
elderly and immunocompromised populations) to fur-
ther establish the public health impact of BC.
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